Interleukin-2 therapies have been seen as promising ways to treat solid tumors, but they have proven challenging because of the ability of IL-2 to both activate and suppress the immune system. Their effectiveness has been limited because of potentially toxic side effects, which have included vascular leak syndrome and pulmonary edema. Aulos Biosciences believes the AI-based approach to computational drug design used for its lead experimental therapy allows it to unlock the power of IL-2 without triggering the concerning side effects of existing therapies. We spoke to Aron Knickerbocker, president and CEO of Aulos Bioscience, about the potential for IL-2 therapies to treat solid tumors, the limits of today's IL-2 therapies, and the AI-based design behind its experimental IL-2 therapy in development.
Why Drug Developers Have a Growing Interest in Targeting Mitochondria
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Targeting a Multitude of CIN in Cancer Cells
The Year in Biotech and What’s Ahead in 2024
Transforming Healthcare with Data
Unlocking Real-World Data to Improve Outcomes
A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech
A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery
Detecting Alzheimer’s Disease Early through a Blood Test
Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology
Building Better and More Affordable Vaccines
Overcoming Resistance to Targeted Therapies
Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies
Using AI to Generate Mini-Protein Therapeutics
Inhibiting Cell Death to Preserve Vision in Retinal Diseases
Leveraging Generative AI to Design Therapeutic Antibodies
Managing Pain without Addiction
Using AI to Match Cancer Patients to their Best Treatment Options
A Venture Capitalist’s View of the Current Biotech Landscape
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths